visualant is a public company whose shares trade under the stock symbol, vsul. the visualant spectral pattern matching™ technology directs structured light onto a substance, through a liquid/gas, or off a surface, to capture a unique chromaid™. when matched against existing databases, a chromaid can be used to identify, detect, or diagnosis markers invisible to the human eye. chromaid scanhead modules can be integrated into a variety of mobile or fixed-mount form factors. the patented technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab–based tests.
Company profile
Ticker
KNW
Exchange
Website
CEO
Phillip Bosua
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CIGAR KING CORP, STARBERRYS CORP, VISUALANT INC, Visualant, INC
SEC CIK
Corporate docs
Subsidiaries
Name: Particle, Inc. • Percent Ownership by Registrant: 100.0% by Know Labs, Inc. ...
IRS number
911948357
KNW stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
17 Apr 24
424B3
Prospectus supplement
12 Apr 24
S-1/A
IPO registration (amended)
9 Apr 24
S-1
IPO registration
28 Mar 24
424B5
Prospectus supplement for primary offering
20 Mar 24
8-K
Entry into a Material Definitive Agreement
20 Mar 24
8-K/A
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
6 Mar 24
8-K
Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution
29 Feb 24
8-K
Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor
27 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.02 mm | 8.02 mm | 8.02 mm | 8.02 mm | 8.02 mm | 8.02 mm |
Cash burn (monthly) | (no burn) | 380.83 k | 978.73 k | 1.27 mm | 459.31 k | 862.83 k |
Cash used (since last report) | n/a | 2.54 mm | 6.52 mm | 8.48 mm | 3.06 mm | 5.75 mm |
Cash remaining | n/a | 5.49 mm | 1.51 mm | -460.39 k | 4.97 mm | 2.28 mm |
Runway (months of cash) | n/a | 14.4 | 1.5 | -0.4 | 10.8 | 2.6 |
Institutional ownership, Q2 2023
2.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 22 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.68 bn |
Total shares | 1.69 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 227.01 k | $229.28 mm |
Fulcrum Capital | 226.49 k | $228.75 mm |
Corrado Advisors | 207.13 k | $209.20 mm |
Geode Capital Management | 154.03 k | $155.57 mm |
Callan Capital | 150.00 k | $151.50 mm |
Millennium Management | 149.45 k | $150.94 mm |
Truadvice | 148.60 k | $128.39 mm |
Bridgeway Capital Management | 100.00 k | $101.00 mm |
NTRS Northern Trust | 78.89 k | $79.68 mm |
Citadel Advisors | 56.91 k | $57.48 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Feb 24 | John E Cronin | Common Stock | Grant | Acquire A | No | No | 0.49 | 16,164 | 7.92 k | 16,164 |
8 Feb 24 | John E Cronin | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 290,411 | 142.30 k | 290,411 |
8 Feb 24 | Timothy M Londergan | Common Stock | Grant | Acquire A | No | No | 0.49 | 16,164 | 7.92 k | 17,164 |
8 Feb 24 | Timothy M Londergan | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 290,411 | 142.30 k | 290,411 |
8 Feb 24 | Larry K Ellingson | Common Stock | Grant | Acquire A | No | No | 0.49 | 16,164 | 7.92 k | 16,164 |
8 Feb 24 | Larry K Ellingson | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 290,411 | 142.30 k | 290,411 |
8 Feb 24 | Jon Pepper | Common Stock | Grant | Acquire A | No | No | 0.49 | 100,000 | 49.00 k | 528,000 |
8 Feb 24 | Jon Pepper | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 500,000 | 245.00 k | 500,000 |
8 Feb 24 | William Arthur Owens | Common Stock | Grant | Acquire A | No | No | 0.49 | 100,000 | 49.00 k | 947,703 |
8 Feb 24 | William Arthur Owens | Option to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 0.49 | 500,000 | 245.00 k | 500,000 |
News
Benchmark Initiates Coverage On Know Labs with Speculative Buy Rating, Announces Price Target of $1
8 Apr 24
Why NetApp Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
1 Mar 24
Know Labs Secures U.S. $12M Funding With Lind Global Fund II LP For Company's Further Execution On Its Clinical Research And Development Initiatives
29 Feb 24
Know Labs Announces The KnowU, Its Wearable Non-Invasive Continuous Glucose Monitor
27 Feb 24
Know Labs Q1 EPS $(0.04) Up From $(0.08) YoY
14 Feb 24
Press releases
Know Labs to Present Clinical Research at the 2024 American Physiology Summit
5 Apr 24
Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor
27 Feb 24
Know Labs, Inc. Reports First Quarter FY2024 Results
14 Feb 24
Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024
7 Feb 24
Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
23 Jan 24